Christine Fox - 20 Nov 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Head of U.S. Commercial
Signature
/s/ Dov Bergwerk as attorney-in-fact for Christine Fox
Issuer symbol
TEVA
Transactions as of
20 Nov 2023
Net transactions value
$0
Form type
4
Filing time
22 Nov 2023, 07:18:44 UTC
Next filing
05 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +253,968 $0.000000 253,968 20 Nov 2023 Ordinary Shares 253,968 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on November 20, 2023, with 63,492 vesting on each of November 20, 2024, November 20, 2025, November 20, 2026 and November 20, 2027.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.